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Shroom-mediated remodeling of the actomyosin cytoskele-
ton is a critical driver of cellular shape and tissue morphology
that underlies the development of many tissues including the
neural tube, eye, intestines, and vasculature. Shroomuses a con-
served SD2 domain to direct the subcellular localization of Rho-
associated kinase (Rock), which in turn drives changes in the
cytoskeletonandcellularmorphologythroughitsability tophos-
phorylate and activate non-muscle myosin II. Here, we present
the structure of the human Shroom-Rock binding module,
revealing an unexpected stoichiometry for Shroom inwhich two
Shroom SD2 domains bind independent surfaces on Rock.
Mutationof interfacial residues impaired Shroom-Rockbinding
in vitro and resulted in altered remodeling of the cytoskeleton
and loss of Shroom-mediated changes in cellular morphology.
Additionally, we provide the first direct evidence that Shroom
can function as a Rock activator. These data provide molecular
insight into the Shroom-Rock interface and demonstrate that
Shroom directly participates in regulating cytoskeletal dynam-
ics, adding to its known role in Rock localization.
The actomyosin cytoskeleton is a dynamic network that
assembles, disassembles, and generates contractile forces to
change the shape of a cell in response to stimuli. Dramatic rear-
rangement of cellular architecture is required for essential pro-
cesses including migration, division, and changes in cell shape,
events that must be executed correctly and efficiently to ensure
the proper development and survival of every organism. Mis-
regulation of the cytoskeleton can result in a variety of birth
defects including exencephaly, spina bifida (1), and congenital
myopathy (2); it also plays a role in other human disease states
including cancer (3), immune function (4), synaptic function
(5), and neural degeneration (6).
Cells utilize the actin cytoskeleton and myosin II to generate
the force needed to control cell shape, motility, and behavior.
The contractile activity of myosin II is largely regulated by the
phosphorylation status of its associatedmyosin regulatory light
chain (MRLC).2 Activity of non-muscle myosin II is stimulated
by several serine/threonine kinases, which phosphorylate
MRLC at Thr-18 and Ser-19 (7, 8) and drive contraction of
F-actin bundles (9, 10). The phosphorylation of MRLC is
opposed by the activity of myosin phosphatase (MYPT), which
decreases phosphorylated MRLC levels and reduces the con-
tractile activity of non-muscle myosin II (11).
Rho-associated kinase (Rock) is a serine/threonine kinase
that both directly and indirectly activates non-muscle myosin
II. Rock has been shown to positively regulate contractility by
phosphorylating MRLC at position Ser-19 (12). Additionally,
Rock phosphorylates MYPT at positions Thr-697 and Ser-854
(13), resulting in inactivation of MYPT and effectively aug-
mentingmyosin II activity by preventing its dephosphorylation
(13–15).
Rock activity has been shown to drive cytoskeletal remodel-
ing associated with cell migration (16), membrane blebbing
(17–19), vasculogenesis (20), and apical constriction (21–23).
The Rock protein is composed of anN-terminal kinase domain,
a large central coiled coil domain, and C-terminal pleckstrin
homology (PH) and cysteine-rich C1 domains (Fig. 1A). Auto-
inhibitory interactions between the kinase and PH/C1 domains
provide a mechanism by which Rock activity is tightly con-
trolled (24–26). Rock can be activated through several mecha-
nisms, the best studied of which is the binding of RhoA-GTP to
the Rho-binding domain within the coiled coil domain of Rock
(27, 28) (see Fig. 1A). Additional mechanisms exist that affect
Rock autoinhibitory interactions including lipid binding to the
PH domain (29) and protease cleavage of the C terminus by
caspase-3 (19) or granzyme B (18). In all of these scenarios,
activation is thought to be achieved by displacement of the
C-terminal PH/C1 motifs from the catalytic domain.
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Members of the Shroom (Shrm) family of cytoskeletal pro-
teins bind to the coiled coil domain of Rock and are required for
epithelial cell shape change (23, 30). Humans and many other
vertebrates have four Shrm isoforms (Shrm1–4), and each iso-
form associates with a distinct population of F-actin, driving its
subcellular localization and subsequent function (31, 32). Shrm
family members share similar domain architecture with two
highly conserved domains called Shrm domain 1 (SD1) and
Shrm domain 2 (SD2) that bind F-actin and Rock, respectively
(22, 23, 31, 33) (see Fig. 1A). Sequences at the N terminus are
more diverse but, in combinationwith SD1, appear tomodulate
subcellular localization (31, 33–35).
The Shrm-Rock interaction module is conserved from Dro-
sophila to humans and has been shown to play a role in the
development of multiple tissues including the neural tube (1,
22), gut (36, 37), eye (38, 39), and vasculature (40). Shrm-Rock
interactions recruit Rock to Shrm-associated regions of the
cytoskeleton where Rock activity can drive specific and local-
ized changes to the cytoskeletal architecture and cellular mor-
phology (23, 30, 33). Finally, the importance of the Shrm-Rock
interaction module has been established in mice where a single
point mutation in the Shrm3 SD2 has been shown to disrupt
Rock binding and result in neural tube defects (21).
Structural data exist for many domains within Shrm and
Rock including the Shrm-binding domain (SBD) of human
Rock1 (41), which forms a parallel coiled coil, consistent with
previous structural data from the RhoA-binding and central
regions of Rock (42, 43). Biochemical analysis identified resi-
dues important for Shrm binding and found them to be posi-
tioned on opposing faces of the Rock coiled coil (41). Surpris-
ingly, the structure of the SD2 domain from Drosophila Shrm
revealed that this conserved domain adopted a three-seg-
mented, antiparallel coiled coil with mutational analysis indi-
cating two Rock-binding sites located 80 Å apart (44). The
two observed structures therefore appeared inadequate to
describe amolecularmechanism for the formation of the Shrm-
Rock binding module.
Here, we present crystal structures of human Shrm2 SD2
determined independently and in a complexwith humanRock1
SBD. The structure of the Shrm-Rock module reveals two two-
segmented, antiparallel coiled coil human Shrm2 SD2 mono-
mers binding to opposing faces of a single parallel coiled coil
dimer of human Rock1 SBD. Our models reveal striking oligo-
meric differences between Drosophila and human Shrm pro-
teins while retaining a similar core structure.We have used this
model to identify critical residues responsible for Shrm-Rock
recognition both in vitro and in vivo. Lastly, we also demon-
strate, using purified components, that the Shrm SD2 can stim-
ulate Rock kinase activity independently of RhoA. These find-
ings indicate that Shrm proteins can both simultaneously
recruit and activate Rock in vivo to control cell morphology.
Results
Architecture of the Shrm-Rock Binding Module—To under-
stand themolecularmechanismdriving formation of the Shrm-
Rock interaction module, we first sought to crystallize and
determine the structure of a Shrm-Rock complex. Previous
binding data indicated that Rock proteins containing additional
coiled coil sequence N-terminal to the SBD bind to Shrmmore
tightly than the minimal SBD. Therefore, we reasoned that
additional contacts between these regions of Rock might be
revealed if we utilized larger fragments of Rock. In an effort to
identify these potential contacts, we expressed and purified a
large portion of human Rock1 (residues 707–946) containing
the SBD core (residues 834–913) as well as the SD2 from
human Shrm2. The resulting complex was subjected to limited
proteolysis, and the progress of digestion was monitored by
native and denaturing PAGE. This resulted in the formation of
a species that migrated farther when analyzed by native PAGE.
This species was extracted from the gel and trypsinized, and the
resulting peptides were identified by mass spectrometry (Fig.
1B). In this analysis, we observed enrichment in Rock peptides
between amino acid positions 750 and 890. Guided by these
data, we attempted to crystallize a variety of Shrm-Rock com-
plexes, generating crystals with several variants of Rock. We
only obtained suitable diffraction data from crystals of the
smallest Shrm-Rock module tested, which contained human
Shrm2 SD2 (residues 1427–1610) and Rock1 SBD (residues
834–913). Diffraction data were weak and highly anisotropic as
was observed for Rock1 (41). The SD2-SBD structure was
refined to 3.57-Å resolutionwith anRwork/free of 27.3/28.7% (see
“Experimental Procedures” and Table 1 for a complete descrip-
tion of the structure determination process).
The asymmetric unit contains four copies of each protein,
comprising two complete Shrm-Rock modules (module A and
module B) (Fig. 1C). Overall, electron density and the resulting
model were best formodule A (chains A–D), and thus all of our
analysis and figures are derived from that module unless noted.
The twomodules are similar to each other (r.m.s.d. of 0.7Åover
310 C atoms) with eachmodule containing one dimer of Rock
SBD with two Shrm SD2 monomers bound on opposing faces
(Fig. 1C). Nearly all of the Shrm SD2 residues were observed in
our structure with the exception of the hinge region where the
quality of the electron density was variable. The dimeric, paral-
lel coiled coil arrangement observed for the Rock SBD is in
general agreementwith other structures of the central region of
Rock (42, 43). However, unlike our previous structure of the
Rock SBD (41), residues 895–913 were disordered.
Human Shrm2 SD2 Adopts an Unanticipated Fold—Prior to
this study, the only structural data for a Shrm SD2 domain was
that of the SD2 domain from Drosophila Shrm (44). In this
structure, an extensive array of protein-protein interactions
betweenDrosophila SD2molecules supported the formation of
a novel three-segmented, antiparallel coiled coil dimer with
internal symmetry (44) (Fig. 2A). The structure of human
Shrm2 SD2 observed in the SD2-SBD complex, however, is
clearly monomeric (Figs. 1C and 2A), forming four helices
(A–D) that come together to form two segments of coiled coil,
one containing helices A and D with helices B and C forming
the second coiled coil segment. A region called the “elbow”
forms a bend between the two segments, and an eight-residue
stretch in themiddle of the SD2, called the “hinge,” forms a turn
that allows the protein to fold back on itself, forming the B/C
segment. The resulting fold is similar to both halves of theDro-
sophila SD2 structure (average r.m.s.d. of 1.7 Å over 168 C
atoms) (Fig. 2A) but lacks significant structural similarity to any
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protein in the structural database. The positions of previously
identified mutants that disrupted homodimerization in Dro-
sophila Shrm SD2 are conserved in human Shrm2 SD2 where
they now form interactions that stabilize the A/D and B/C seg-
ments. Electrondensity in the hinge region is of variable quality;
however, density for backbone residues can be observed for
several of the SD2 molecules (Fig. 2B). The hinge spans human
Shrm2 SD2 residues Leu-1519 to Pro-1525, a region previously
termed the “symmetry point” as it was located directly in
between the two structurally identical halves ofDrosophila SD2
(44) (Fig. 2A). The hinge sequence is absent inDrosophila Shrm
andmay restrict its ability to form a B/C segment in themanner
that human Shrm SD2 does.
One significant difference between the two Shrm structures
is the presence of Rock SBD in the structure of our complex.We
therefore sought to compare human Shrm2 and Drosophila
Shrm SD2 proteins in the absence of Rock. First, we subjected
purified SD2 domain from Drosophila Shrm, human Shrm2,
and the Shrm-Rock complex to size exclusion chromatography
(Fig. 2C). As described previously, we observed two species
when performing size exclusion chromatography with Dro-
sophila SD2, a major species that we observed to be a dimer in
our crystals (44) and a secondminor peak, whichwas presumed
to be monomeric. We also observed two species for the Shrm-
Rock complex with the major species being significantly larger
than the SD2 domain from either human or Drosophila. We
FIGURE 1.Architecture of the humanShrmSD2-Rock SBD complex.A, signaling cascade anddomain diagramof human Shrm2 and humanRock1 proteins.
B, positions of peptides identified by mass spectrometry from isolated Shrm-Rock complexes digested with trypsin. The observed Shrm-binding site on Rock
is indicated in green.C, ribbondiagramof the hShrm2 SD2-hRock1 SBDbindingmodule. Two views are shownwith a 90° rotation in between as indicated. Two
SD2monomers (orange) andoneSBDdimer (blue) are shownwith important regionswithin each indicated.RBD, Rho-bindingdomain;nm-myosin, non-muscle
myosin.
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observed only a single species for human Shrm2 SD2 with a
retention volume that indicates a smaller radius of gyration
under the same conditions, consistent with a smaller mono-
meric species rather than the extended, dimeric conformation
ofDrosophila SD2. In all cases, the apparent molecular weights
were significantly higher than expected presumably due to the
extended nature of these proteins.
To ascertainwhether therewas a conformational change that
resulted upon Rock binding andmight explain the difference in
SD2 conformation, we crystallized and determined the struc-
ture of human Shrm2 SD2 in the absence of Rock, refining
against native data to 3.3-Å resolutionwith anRwork/free of 24.6/
29.9% (Fig. 2A andTable 1).We observed that, in the absence of
Rock, human Shrm2 SD2 adopts a monomeric fold, which is
very similar to human SD2 in complexwith Rock (r.m.s.d. of 0.9
Å over 147 C). Although the electron density for the hinge
region was once again of variable quality, we were able to fit the
hinge sequence into the electron density in one of the twomol-
ecules in the asymmetric unit, demonstrating that this feature is
characteristic of the human Shrm2 SD2 fold. From these data,
we conclude that, in contrast toDrosophila Shrm, the SD2 from
human Shrm2 is a monomer and that formation of the 1:2:1
(Shrm-Rock2-Shrm) arrangement we observed for the human
Shrm-Rock complex does not require any dramatic conforma-
tional changes within the SD2.
The Molecular Basis for Shrm-Rock Recognition in Vitro—
The four Shrm-Rock interfaces within the asymmetric unit
bury an average of 887.2 Å2 of surface area. Calculating shape
complementarity for each interface yielded values ranging from
0.54 to 0.61, which is consistent with values for the Rock SBD
dimer interface (0.56) as well many other protein-protein inter-
faces, particularly those that have multiple binding interfaces
(45). Given that the Shrm-Rock interaction is conserved
throughout metazoans, we hypothesized that the interface
would be enriched in highly conserved and invariant residues.
To test this, we generated amultiple sequence alignment of the
Shrm2 SD2 (23 sequences) and the Rock1 SBD (33 sequences).
Mapping sequence conservation onto the surface of both pro-
teins revealed a large patch of residues with 95% identity
within our alignment that cluster near the N terminus of the
Rock SBD. This conserved patch also correlates with the loca-
tion of the Shrm-Rock binding interface observed in our struc-
ture (Fig. 3). Sequence conservation within the Shrm2 SD2 is
more extended with smaller patches existing on both faces of
the molecule. The largest patch of residues with95% identity
in our alignment nevertheless corresponds with the observed
binding interface. It also includes residue Arg-1508, a position
that is conserved in all SD2 and whenmutated in Shrm3 results
in neural tube defects in a mouse model (Fig. 3) (21).
To demonstrate that the Shrm-Rock recognition we
observed in our crystal is the biologically relevant interface, we
designed several single point mutations to probe the SD2-SBD
interface and identify residues critical to binding.We generated
mutant proteins in the context of fluorescent fusions of Shrm
SD2 (His10-mRuby2-1427–1610) and Rock SBD (His10-Clover-
707–946) (46). We assayed the ability of purified Shrm2 SD2
variants (L1501A, L1548A, and K1487A) to bind Rock1 SBD by
native PAGE. Leu-1501 and Leu-1548 are both buried within
the binding interface (Fig. 4,A andB), and alanine substitutions
at those positions abolish binding (Fig. 4E). Lys-1487 is pre-
dicted to interact with Rock Glu-862 at the periphery of the
binding interface where it makes one of a relatively small num-
ber of hydrogen bonds observed within the interface (Fig. 4A).
TABLE 1
Data collection and refinement statistics
Human Shrm2 SD2 Human Shrm-Rock complex
Protein Data Bank code 5F4Y 5F5P
Data collection
Space group C2221 P212121
Cell dimensions a, b, c (Å) 90.89, 110.00, 118.86 97.59, 133.80, 135.87
Reflections
Total 280,990 1,327,044
Unique 8,552 21,121
Resolution (Å) 50.00–3.29 (3.36–3.29)a 50.00–3.57 (3.63–3.57)
Rmerge (%)b 8.0 8.0
I/I 23.7 (2.26) 24.5 (1.72)
Completeness (%) 92.7 (91.8) 97.8 (97.9)
Redundancy 5.6 5.3
Wilson B-factor 115.4 130.0
Refinement
Resolution (Å) 14.93–3.29 (3.46–3.29) 20–3.57 (3.74–3.57)
Rworkc/Rfreed (%) 24.6/29.9 (30.8/39.0) 27.3/28.7 (51.1/47.9)
Number of atoms
Protein 5,198 15,406
B-factors (Å2) 125.1 149.8
r.m.s.e deviations
Bond lengths (Å) 0.003 0.002
Bond angles (°) 0.45 0.54
Ramachandran
Favored (%) 98.1 98.68
Allowed (%) 1.9 1.32
Clash score 1.54 1.49
a Values in parentheses are for highest resolution shell.
b Rmerge ((I I))/(I) where I is the average intensity of multiple measurements.
c Rwork hklFobs(hkl) Fcalc(hkl)/hklFobs(hkl).
d Rfree represents the cross-validation R factor for 10.1% (Shrm SD2) or 5.3% (Shrm-Rock complex) of the reflections against which the model was not refined.
e Root mean square.
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Despite its peripheral location, the K1487A mutant also abol-
ishes binding (Fig. 4E).
We generated Rock interface mutations (Y851A, F852A,
L855A, Q859A, and E862A) in a similar manner, once again
testing them for complex formation by native PAGE. Here, we
observed that F852A and L855A substitutions in the hydropho-
bic center of the interface cannot support complex formation,
whereas substitutions of residues in the periphery (Y851A,
Q859A, and E862A) had little to no effect on binding in this
assay (Fig. 4C). The effect of substituting Glu-862 in Rock was
surprising as it was observed hydrogen bondingwith the critical
Shrm residue Lys-1487 in our structure. Previous studies have
demonstrated that an alanine triple mutant in Rock1, K857A/
T858A/Q859A, was unable to bind Shrm3. These results indi-
cate that either the hydrogen bond between Rock Gln-859 and
Shrm Asn-1551 is, on its own, not essential for the Shrm-Rock
interaction in vitro; that Lys-857 and Thr-858 contribute sig-
nificantly to binding; or that these three residues contribute
more to Shrm3 binding than Shrm2. The purified proteins used
in this assay were subjected to limited proteolysis using 0.025%
trypsin (Fig. 4, D and F) and in all cases were found to behave
likewild type, indicating that the indicated substitutions had no
effect on overall structure. Together, these data are consistent
with our previous biochemical analysis performed in the
absence of structural information on the binding interface (21,
30, 41, 44) and pinpoint residues within both Shrm and Rock
that are critical for complex formation in vitro.
Changes in the Shrm-Rock Interface Block Shrm-mediated
Regulation of the Cytoskeleton—We next sought to determine
whether single point mutants that did not support binding in
vitro would be functional within a cellular context. To do this,
we substituted human Shrm2 SD2 or the SD2 with selected
pointmutants into amodified pCS2 vector containing an endo-
lyn targeting sequence (amino acids 1–187) (47) fused to amino
acids 1372–1572 ofmShrm3.This systemallows us to target the
SD2 to the apical surface of cells where we have previously
shown that mouse Shrm2 and Shrm3 SD2motifs are both nec-
essary and sufficient to cause apical constriction in polarized
epithelial cells (23, 31). Using this system, we demonstrate that
human Shrm2 SD2 can also elicit apical constriction similarly
to mouse Shrm3 SD2 (Fig. 5, B and C) and consistent with apical
constriction assays usingmouse Shrm2 SD2 (31). Introducing the
K1487A, L1501A, or L1548Avariant into this assay, we found that
all three proteins are stably expressed and targeted to the apical
surface but are unable to trigger apical constriction to any appre-
ciable degree (Fig. 5,D–F). Thus,we conclude that the Shrm-Rock
interface that we observed in our crystal structure is critical for
both binding to Rock in vitro and for SD2-mediated changes in
cellular morphology in vivo.
To ensure that the loss of apical constriction observed in our
mutants is due to a defect in Shrm-mediated recruitment of
Rock, we co-transfected MDCK cells with both the endolyn-
tagged Shrm variants and a Myc-tagged Rock SBD (residues
681–942). We stained these transfected cells to determine the
localization of both Shrm and Rock proteins. Although wild-
type mShrm3 SD2 and human Shrm2 SD2 can recruit Rock to
the apical surface ofMDCKcells (Fig. 5,H and I), Shrmmutants
K1487A, L1501A, and L1548A as well as a mShrm3 construct
lacking the SD2 domain cannot (Fig. 5, G and J–L). We con-
clude that the phenotype observed in Fig. 5, D–F, is due to the
loss of Shrm-mediated Rock recruitment to the apical plasma
membrane.
Shrm SD2 Can Directly and Independently Activate Rock
Kinase—Intramolecular autoinhibitory interactions between
the N-terminal kinase domain and C-terminal regions of Rock
are believed to hold Rock in an “inactive” state in which only
basal levels of activity can be measured (24, 25). It has been
established that binding of Shrm localizes Rock to various sub-
cellular locales where Rock activity drives cytoskeletal rear-
rangement (23, 31). However, it has remained unclear whether
the primary role of Shrm-Rock interactions was to govern Rock
FIGURE 2. Structural similarities and oligomeric differences between the
Drosophila Shrm and Human Shrm2 SD2 domains. A, crystal structures of
Drosophila and human Shrm SD2 domains superposed over the SD2 domain
from the Shrm-Rock complex. Both human SD2 domains are highly similar to
either half of the Drosophila SD2 structure. B, electron density (2Fo Fc con-
toured at 1.0) of the hinge region in human Shrm2 SD2 from the Shrm-Rock
complex. C, indicated species of human Shrm SD2,Drosophila Shrm SD2, and
the human Shrm-Rock complex were resolved by size exclusion chromatog-
raphy using a Sephacryl S200 column. The elution of globularmolecularmass
standards are indicated for comparison. Homogenous species with Gaussian
profiles indicated by an asteriskwere used in structural studies. D, SDS-PAGE
showing the composition of the species a–e.
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localization or whether Shrm also possesses the ability to
relieve Rock autoinhibition directly. To address whether
human Shrm2 SD2 can function as a direct Rock activator, we
performed an on-bead kinase assay (48) using purified SD2
domains and His10-tagged full-length Rock1 protein expressed
in and purified fromCOS7 cells. Rock1 kinase was immobilized
FIGURE 3. The conserved SD2-SBD interface.Conservation from amultiple sequence alignment of 23 Shrmor 33 Rock1 proteinswasmapped onto a surface
representation of each protein. Residues with over 95% identity within this alignment are colored orange for Shrm (left box), and residues over 85% identical
(light blue) and over 95% identical (blue) are indicated on the Rock1 surface (lower right box). The boundaries of the observed binding interface are outlines for
both proteins. A ribbon diagram of the complex is shown for reference.
FIGURE 4. The molecular basis for Shroom-Rock recognition. A and B, ribbon diagram of the Shrm-Rock interface featuring important residues as sticks.
Residues previously shown tomediate Shrm-Rock interactions are indicated in green, additional residues shown tomediate interactions as a part of this study
are colored yellow, and the position Arg-1508 shown to mediate neural tube defects in mice is shown in magenta. Selected hydrogen bonding interactions
within the interface are indicatedwith black dotted lines. C and E, mutants in the Shrm-Rock interface block complex formation.Wild-type ormutant Shrm SD2
(mRuby-SD2)or Rock1SBD (residues707–946 fused toClover)weremixedas indicated, and their ability to formacomplexwas assayedbynativePAGE, imaged
at 460 or 630 nm, and presented as a false colored overlay. D, WT and mutant Rock1 (residues 707–946) proteins were subjected to limited proteolysis using
0.025% trypsin, and sampleswere taken at the indicated time points. In this assay, themutant proteins behaved similarly towild type. F, limited proteolysis for
Shrm SD2 (residues 1427–1610) mutants was performed as in D.
Structure of the Human Shrm-Rock Complex
DECEMBER 2, 2016•VOLUME 291•NUMBER 49 JOURNAL OF BIOLOGICAL CHEMISTRY 25369
 at U
niversity of Pittsburgh on M
ay 28, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
onto beads and washed thoroughly to remove any potential
activating proteins (48).We then assayed the ability of Rock1, in
the presence and absence of human Shrm2 SD2, to phosphor-
ylate a purified substrate consisting of amino acids 658–714 of
MYPT, which contains the phosphorylation site at Thr-696
(13). Rock activity wasmonitored viaWestern blotting using an
-pMYPT antibody and normalized to Rock1 signal. As shown
in Fig. 6, Rock1 kinase has basal activity for theMYPT substrate
in the absence of activators and is stimulated by the addition of
the canonical Rock activator arachidonic acid (50 M). This
activity is nearly abolished in the presence of the Rock-specific
inhibitor Y-27632 as reported previously (29, 49) (Fig. 6A).
We then asked whether wild-type and mutant Shrm2 SD2
domains could also activate Rock. In this assay, the addition of
wild-type Shrm2 SD2 at a concentration of 1.5 M resulted in a
3.5-fold stimulation of Rock activity over basal levels, consis-
tent with RhoA-mediated stimulation of Rock activity (28).
Addition of L1501A mutant Shrm2 SD2 reduced the levels of
stimulation to 1.6-fold, indicating that the Shrm-mediated
stimulation we observed is specific for the Shrm-Rock binding
interface visualized crystallographically. These data demon-
strate that Shrm is a direct activator of Rock, and thus its role in
regulating changes to the actomyosin network extends beyond
localization and recruitment of Rock. Together with the cellu-
lar assays described earlier, we conclude that the Shrm SD2,
through the Shrm-Rock binding module, elevates pMYPT lev-
els and thereby levels of active non-muscle myosin at the apical
surface. Through this mechanism, the Shrm SD2 domain both
regulates Rock activity and positions it properly within the cell,
generating localized forces that lead to changes in cellular
morphology.
Discussion
Structure of the Shroom-Rock Complex—The interaction
between Shrm family proteins and Rock is critical for the devel-
opment of many tissues, but the molecular basis for this inter-
FIGURE 5. ShrmSD2 and Rock SBDpointmutations disrupt binding in vitro. A–F, MDCK cells were transiently transfected on Transwell filters with the indicated
constructs and stained to detect Shrm (green) and ZO-1 (red). Scale bars represent 10m. Images are projections of 0.5-mconfocal sections.G–L, MDCK cells were
transiently co-transfected on Transwell filters with Myc-Rock (residues 681–942) and the indicated constructs and then stained to detect Shrm (green) or Myc (red).
Scale bars represent 10m. Images are projections of 0.5-mconfocal sections. ap., apical surface; ba., basolateral surface; hSD2, human SD2.
FIGURE 6. Shrm SD2 can directly activate Rock1 kinase. A, magnetic
nickel-nitrilotriacetic acid resin coated with full-length (FL) Rock1 were
incubated in a kinase assay containing MYPT. Samples were analyzed by
Western blotting using antibodies to pMYPT and Rock1. B, the effect of the
Shrm2 SD2 variant L1501A on Rock activation. pMYPT levels were normal-
ized to Rock1 enzyme signal and Rock1 activity was compared with the
Rock1 alone basal level and reported as the mean with error bars repre-
senting the standard deviation from five independent replicates. A stu-
dent t-test was used to calculate p-values with statistically significant val-
ues indicated with an asterisk.
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action is not fully understood. We have crystallized and deter-
mined the structure of the Shrm-Rock binding module in an
effort to identify significant interactions driving complex for-
mation. Consistent with previous results, the SBD of Rock is a
parallel coiled coil dimer when bound to Shrm2 SD2 (41, 42).
The human Shroom2 SD2, however, is monomeric both when
crystallized independently and in the context of a Shrm-Rock
complex. Interestingly, our model indicates that two SD2 pro-
teins are capable of interacting with the SBD coiled coil at the
same time, and we did not observe any potentially cooperative
interactionsbetweenSD2molecules.Previousquantitativemea-
surements of binding affinity have shown that longer versions
of the Rock coiled coil region (amino acids 707–946) bind Shrm
SD2 with higher affinity than the minimal SBD described here
(41), suggesting that additional Rock residues not contained
within our structure may mediate contacts within the Shrm
SD2 domain. We expect these additional contacts to be made
through conserved surfaces on the SD2.Wenote that our struc-
ture reveals three such surfaces on the SD2 domain that are not
occupied by the Rock SBD, although the function of these is
currently unknown (Fig. 3). One, containing residue Lys-1582,
is located in a groove between the A/D and B/C segments adja-
cent to the observed Rock-binding site. The second site, con-
taining Glu-1513, is located on the opposite face of the B/C
segment from Arg-1508 that houses several highly conserved
and surface-exposed residues, suggesting that it might mediate
a protein-protein interaction. The third site is the conserved
patch containing Leu-1440 and Gln-1602, located on the A/D
segment. Substitutions in this patch did not block Shrm-Rock
complex formation or the ability to support apical constriction
(44), suggesting that they do not play a primary role; however,
these assays are qualitative, and thus we cannot exclude the
possibility that this surface mediates a minor Shrm-Rock con-
tact that improves Shrm-Rock affinity. Another possibility is
that these surfaces on Shrm mediate interactions with other
proteins. To date, besides Rock, only Scribble has been sug-
gested to bind the SD2motif of Shrm2. Interestingly, this inter-
action appears to be mediated by the phosphorylation of Scrib-
ble by Rock (50), implying that the Scribble recognition surface
on the SD2 domain should both accommodate and specifically
recognize this post-translational modification.
OligomericDifferences betweenDrosophila andHumanShrm
SD2—Previous structural data revealed that the SD2 domain of
Drosophila Shroom adopts a unique three-segmented, antipar-
allel coiled coil dimer fold (44). This is a striking difference from
the two crystal structures presented here that both capture
human Shrm2 SD2 domain in a monomeric state. It is possible
that the fold captured in the Drosophila Shrm SD2 structure is
that of an inactive, unbound conformation of Shrm SD2 that
changes when the domain associates with its binding partner.
The Drosophila Shrm SD2 conformation could also be the
result of unique stresses present in crystallization reactions, or
the precise nature of the protein construct used facilitated an
extreme domain swapping event. Finally, an evolutionary dif-
ference between the two proteins might explain these differ-
ences. Importantly, although the domains differ in their oligo-
meric state, the locations of key residues (Leu-1467, Leu-1509,
and Lys-1453 in Drosophila Shrm SD2) within the Rock-bind-
ing site are conserved in both SD2 proteins. It remains to be
determined whether human Shrm is capable of dimerization,
but we propose that it interacts with the SBD of Rock as a
monomer.
The Role of the Shrm-Rock Signaling Module in Rock
Regulation—When its activity is not needed, Rock is believed to
reside in an autoinhibited state in which its C-terminal PH/C1
domains directly bind to its N-terminal kinase domain (24, 51).
Recent electron microscopy data on full-length Rock2 have
sought to challenge this view, suggesting that instead of auto-
inhibition Rock regulation is spatially organized within the cell
at a distance governed by the length of its coiled coil region (52).
This is in contrast to existing data (24, 51, 53) demonstrating
protein-protein interactions between C-terminal regulatory
sequences and the kinase domain. Furthermore, binding events
within the regulatory regions of Rock have been demonstrated
to alter Rock activity. It is possible that the inability to observe
autoinhibition or stimulation of Rock2 activity reflects a differ-
ence in the regulatory mechanisms between Rock1 and Rock2.
Mutational data suggest that phosphorylation of the activation
loop is unlikely to be relieving a regulatory barrier for activity
(52). Alternatively, it is possible that the Sf9-purified Rock2
used in that study was trapped in an activated state by the pres-
ence of a co-purifying activator or that the phosphorylation
events observed within the C-terminal sequences of Rock2 at
positions 1352–1353 prevent autoinhibitory interactions. It
will be interesting to see whether Rock2 activity can be stimu-
lated in a Shrm-mediated manner. We predict that it can be as
important residues within the Rock1-Shrm interface are con-
served in Rock2. However, Rock2 may use an entirely different
regulatory mechanism.
We have previously shown that Rock binding to RhoA is not
essential for Shrm-induced apical constriction of MDCK cells
(41). However, this does not eliminate the possibility of co-
operation between Shrm andRhoA for regulating Rock in other
biological process. The binding sites in Rock for Shrm and
RhoA are adjacent but do not overlap. It will be interesting to
test whether there are cooperative interactions between Shrm
and RhoA that influence binding of either of these partners to
Rock as the available crystal structures suggest that simulta-
neous binding is reasonable (41, 42). It remains to be deter-
mined what effect this might have on kinase activation.
Conservation of critical residues within the already highly
conserved SD2 domainmakes it an attractive prediction that all
Shrm proteins retain the ability to activate Rock directly as we
have shown here. Internal cleavage by caspase-3 and granzyme
B in Rock1 and Rock2, respectively, also activate Rock (18, 19)
but through a differentmechanism. It is interesting to note that
these cleavage sites are located C-terminal to the Shrm-binding
site on Rock. This would suggest that Shrm proteins could still
play a role in regulating Rock distribution even under condi-
tions in which the kinases themselves are activated by cleavage.
This would add an additional layer of Shrm-mediated regula-
tion of Rock activity during certain in vivo processes.
Many studies have aimed to understand the mechanisms of
Rock activation and autoinhibition in an effort to design thera-
peutic drugs to down-regulate Rock activity. The widespread
role Rock plays as a cytoskeletal regulator makes it both an
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attractive and challenging target for drug design, so informa-
tion on the specificmolecularmechanisms of Rock regulation is
immensely valuable.One such study has already shown the use-
fulness of an inhibitor of the Shroom3-Rock2 interaction in
stimulating axon outgrowth during repair of neural tissue (54).
We anticipate that the structural information provided by our
investigation will inform on more targeted drug development
for this highly conserved interaction.
Experimental Procedures
Protein Expression and Purification—Coding sequences for
human Rock1 (residues 834–913) and human Shrm2 (residues
1427–1610) were amplified by PCR and cloned into pET151-D/
Topo (Invitrogen). Human Shrm2 SD2 (residues 1427–1610)
was expressed in BL21(DE3)-Gold cells (Agilent) using autoin-
duction media (55). Cells were harvested by centrifugation and
lysed by homogenization. Lysates were cleared by centrifuga-
tion at 30,000	 g, and proteins were purified using nickel affin-
ity purification (Qiagen) followed by TEV protease digestion
and a second round of nickel affinity purification to remove the
His10 tag. The protein was then further purified via anion
exchange and size exclusion chromatography. The same strat-
egy was also used to purify human Rock1 (residues 834–913).
Shrm SD2 and Rock SBD proteins used in the native PAGE
binding assayswere expressed as fusions containingN-terminal
His10-Ruby (Shrm SD2) or His10-Clover (Rock) tag using a
modified pET28a vector. The proteins were purified as
described above, omitting the TEV cleavage and second nickel
column steps to preserve the fluorescent tag as needed.
Generation of SBD-SD2 Complex for Crystallography—
Human Shrm2 SD2 and Rock1 SBD were purified, then mixed
at a 2:1 Rock:Shrm ratio, and dialyzed into buffer containing 50
mMNaCl and 20 mM Tris at pH 8.0 overnight. Following dialy-
sis, size exclusion chromatography was performed, and peak
fractions containing homogenous SBD-SD2 complex were
identified by both SDS- and native PAGE and concentrated to
5.3 mg/ml prior to crystallization.
Crystallization—Crystals of the SD2-SBD complexwere gen-
erated via the vapor diffusionmethod using awell solution con-
taining 20.5% PEG 3350 and 233mM ammonium chloride. Rec-
tangular prism-shaped crystals were cryoprotected in mother
liquor supplemented with 30% glycerol and then flash frozen in
liquid nitrogen prior to data collection. Human Shrm2 SD2
crystals were generated using a well solution containing 20%
PEG 3350, 200 mM magnesium chloride, and 100 mM Tris, pH
8.5, and cryoprotected in a similar manner.
Structure Determination—Diffraction data were collected at
theNational Synchrotron Light Source at BrookhavenNational
Laboratory on Beamline X25 using a Pilatus 6M detector. Inte-
gration, merging, and scaling of the diffraction data were per-
formed using HKL2000 (56).
Crystals of the Shrm-Rock complex belong to the space
group P212121. Diffraction was weak and anisotropic, extend-
ing to only 5.3 Å along the a* axis (UCLA Anisotropy server
(58)). Based on this analysis as well as values for completeness
and CC* (57), we chose to truncate the data at 3.57-Å resolu-
tion. Phases were determined through molecular replacement
using searchmodels generated from the structure of the SBD as
well as fragments of Drosophila SD2 (Protein Data Bank codes
4L2W and 3THF, respectively). Refinement was carried out in
PHENIX (59) using rigid body and group B-factor refinement
with non-crystallographic symmetry restraints.Model building
and positional refinement were performed in Coot (60). Crys-
tals of human Shrm2 SD2 belong to space group C2221 and
were only mildly anisotropic. Phases were determined using
molecular replacement using a monomer of SD2 from the
Shrm-Rock binding module as a search model. Rigid body and
B-factor refinementwere performed inPHENIX (59), andman-
ual model building was performed within Coot (61, 62). Mol-
Probity (62) was used to assess model validity, and images were
generated using PyMOL (63).
Native PAGE Binding Assays—Binding reactions containing
25 M SD2 and 15 M SBDwere carried out in 8% glycerol, 125
mM NaCl, 1 mM -mercaptoethanol, and 25 mM Tris, pH 8.0,
and incubated at room temperature for 5 min before being
resolved by 10% native PAGE and quantified using ImageJ (64).
Limited Proteolysis and Mass Spectrometry—Complexes of
Shrm and Rock were isolated and truncated by limited proteol-
ysis using trypsin. After isolation of gel slices representing the
truncated complexes from native gels, the slices were subject to
in-gel trypsin digestion to generate tryptic peptides, whichwere
identified by tandemMS using a ThermoFisher Orbitrap mass
spectrometer (Fred Hutchinson Cancer Research Center Pro-
teomics Facility). Peptide Prophet (65) was used to evaluate the
validity of peptide identifications, and we eliminated peptides
with a score
0.85 (
2.5% false discovery rate).
Cell Culture and in Vivo Cytoskeletal Assay—COS7 cells
were grown in DMEM supplemented with 10% FBS, L-gluta-
mine, and penicillin/streptomycin. Transient transfection was
performed in 6-well plates using 300,000 cells, 2 g of DNA,
and 5 l of Lipofectamine/well. Transfected cells were incu-
bated for 24 h before processing. MDCK cells were grown in a
similar manner using Eagle’s minimum essential medium.
pCS2 endolyn-Shrm chimeric constructs were generated as
reported previously (23). For analysis of the cytoskeleton, cells
werewashed three times in PBS, fixed in 100%MeOH for 5min,
washed three times with PBST, and then incubated with pri-
mary antibody in PBST for 1 h. Antibodies used were UPT132
(1:200), anti-ZO-1 (1:200) (Promega), and 9E10 (1:100)
(ATCC). Cells were washed three times in PBST and then incu-
bated for 1 h with secondary antibody (Alexa Fluor 488- and
568-conjugated antibodies; 1:400). Cells were washed three
times with PBST and then finally mounted on slides using
Immuno-Fluore mounting medium (MP Biomedicals).
Kinase Activity Assay—Full-length human Rock1 coding
sequences were cloned into a modified pCAG-myc vector con-
taining aHis10 tag andTEVprotease cleavage site. This plasmid
was then transfected into COS7 cells using Lipofectamine. 24 h
post-transfection, cells were rinsed with PBS and then resus-
pended in lysis buffer containing 50 mMHEPES, 300 mMNaCl,
5 mM -mercaptoethanol, 10% glycerol, 20 mM imidazole, and
0.05% Nonidet P-40. Lysates were cleared by centrifugation,
and the soluble fraction was subjected to nickel affinity chro-
matography using magnetic nickel beads (Thermo Scientific).
Full-length Rock1 protein was retained on the nickel resin and
washed with lysis buffer and with lysis buffer containing 1 M
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NaCl prior to washing into reaction buffer before being used in
activity assays.
Kinase activity assays were carried out by incubating 1 l of
magnetic nickel beads coated with full-length Rock1 in a 25-l
reaction using a reaction buffer consisting of 20 mM Tris-HCl,
pH 7.0, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl2, and 5 M
MYPT with and without SD2, Y-27632, or 50 M arachidonic
acid. Reactions were started with the addition of 10 M ATP
and then incubated at 30 °C for 10 min. Substrate phosphory-
lation was evaluated by Western blotting using a primary anti-
body against pMYPT (Millipore). Quantification was per-
formed using ImageJ (64).
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